A practical reference on albumin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid, may form a loose cake |
| Solubility class | Soluble in water | Practically insoluble in nonpolar solvents |
| Storage temperature, solid | -20 °C or below | Desiccated and protected from light |
| Storage temperature, liquid | 2-8 °C | Refrigerated, not frozen |
| Typical identity method | LC-MS | Observed mass compared with calculated mass |
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
=== Regulatory status === This medication first reached market in 1973. It is approved in 21 countries worldwide, which does not include its home country of Denmark. It was taken off the approved list in India in 2014, citing a lack of required information such as mandatory clinical trial results in its 1998 approval decision. It is approved in China.
A variety of contractors are involved in the production, management, and distribution of UGRs and their contents, including (as of 2023) ABC Ventures, AmeriQual, Atlantic, Chef Minute Meals, Club Tex, Envision, Inc., Epic Foods, Gossner Foods, Hershey, HOIST, LC Industries, Nex-Xos, OhSix, Oregon Freeze Dry, Sterling Foods, Sopakco, Valley Foods, Werling Meats, and Wornick. More than 60,000 UGRs are produced each year. UGRs are supplied by the DLA's Operational Rations Division. UGRs, like other rations, cannot be sold to individuals, and are only supplied or sold to the U.S. military, the DoD, the federal government, government employee commissaries, government contractors (if their contract specifically permits such purchases), foreign governments with authorized contractual relationships, and civilians as humanitarian aid.
==== Droplet sorting ==== Droplet sorting in microfluidics is an important technique, allowing for discrimination based on factors ranging from droplet size to chemicals labeled with fluorescent tags within the droplet, stemming off of the work done to sort cells in Flow Cytometry. Within the realm of droplet sorting there are two main types, bulk sorting, which uses either active or passive methods, and precise sorting, which relies mainly on active methods. Bulk sorting is applied to samples with a large number of droplets (> 2000 s−1) that can be sorted based on intrinsic properties of the droplets (such as viscosity, density, etc.) without checking each droplet. Precise sorting, on the other hand, aims to separate droplets that meet certain criteria that is checked on each droplet. Passive sorting is done through control of the microfluidic channel design, allowing for discrimination based on droplet size. Size sorting relies on the bifurcating junctions in the channel to divert the flow, which causes droplets to sort based on how they interact with the cross section of that flow, the shear rate, which relates directly to their size. Other passive methods include inertia and microfiltration, each having to do with the physical properties, such as inertia, and density, of the droplet. Active sorting uses additional devices attached to the microfluidic device to alter the path of a droplet during flow by controlling some aspect, including thermal, magnetic, pneumatic, acoustic, hydrodynamic and electric control.
Sources: en.wikipedia.org
== Urban hydroponics == Urban hydroponics refers to the use of soilless cultivation systems in city environments, including apartments, rooftops, and other indoor spaces. These systems have been explored in response to challenges related to urban food access. According to the United States Department of Agriculture, more than 19 million people in the United States live in low-income neighborhoods with limited access to supermarkets or large grocery stores, areas often referred to as food deserts. In these contexts, hydroponic systems can be used as a method to grow vegetables such as lettuce, spinach, and herbs indoors. Urban hydroponic systems are generally designed to operate within small spaces. Commercially available units include vertical towers, countertop kits, and window-mounted structures, many of which rely on artificial lighting and water circulation to deliver nutrients directly to plant roots. These configurations are intended to support plant growth in environments with limited natural sunlight and no access to soil. Some hydroponic systems are marketed toward individual consumers and households. While larger systems may require significant investment, smaller-scale models are available for individual use. Reports suggest that such systems can produce a range of crops year-round, though yield and cost-efficiency vary by setup and user experience. Hydroponic systems have also been studied for their resource efficiency.
== Structure == The structure of the human PLC has been determined using single-particle electron cryo-microscopy (cryo-EM). The PLC, measuring 150 Å by 150 Å and with a total height of 240 Å, is organized around the Transporter associated with Antigen Processing (TAP). It includes molecules such as tapasin, calreticulin, ERp57, and Major Histocompatibility Complex class I (MHC-I), arranged in a pseudo-symmetric pattern.
Albinism–black lock–cell migration disorder of the neurocytes of the gut–deafness syndrome (ABCD syndrome) Albinism–deafness syndrome (Woolf syndrome, Ziprkowski–Margolis syndrome) Alezzandrini syndrome Argyria Arsenic poisoning Berlin syndrome Pigmentation changes caused by the bioaccumulation of pigments, e.g.
Sources: en.wikipedia.org
The zangfu (脏腑; 臟腑; zàngfǔ) are the collective name of eleven entities (similar to organs) that constitute the centre piece of TCM's systematization of bodily functions. The term zang refers to the five considered to be yin in nature – Heart, Liver, Spleen, Lung, Kidney – while fu refers to the six associated with yang – Small Intestine, Large Intestine, Gallbladder, Urinary Bladder, Stomach and San Jiao. Despite having the names of organs, they are only loosely tied to (rudimentary) anatomical assumptions. Instead, they are primarily understood to be certain "functions" of the body. To highlight the fact that they are not equivalent to anatomical organs, their names are usually capitalized. The zang's essential functions consist in production and storage of qi and xuě; they are said to regulate digestion, breathing, water metabolism, the musculoskeletal system, the skin, the sense organs, aging, emotional processes, and mental activity, among other structures and processes. The fǔ organs' main purpose is merely to transmit and digest (傳化; chuán-huà) substances such as waste and food. Since their concept was developed on the basis of Wǔ Xíng philosophy, each zàng is paired with a fǔ, and each zàng-fǔ pair is assigned to one of five elemental qualities (i.e., the Five Elements or Five Phases). These correspondences are stipulated as:
Degarelix, sold under the brand name Firmagon among others, is a hormonal therapy used in the treatment of prostate cancer. Testosterone is a male hormone that promotes growth of many prostate tumours and therefore reducing circulating testosterone to very low (castration) levels is often the treatment goal in the management of advanced prostate cancer. Degarelix has an immediate onset of action, binding to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocking their interaction with GnRH. This induces a fast and profound reduction in luteinizing hormone (LH), follicle-stimulating hormone (FSH) and in turn, testosterone suppression.
The Beighton score can be used to determine generalised joint hypermobility (GJH) related to hypermobility syndrome. The newer term "generalised hypermobility spectrum disorder" includes people with generalised joint hypermobility, often determined using the Beighton score, and other symptoms. Those who do not meet the Beighton score criteria may be diagnosed with historical joint hypermobility spectrum disorder, peripheral hypermobility spectrum disorder, or localised hypermobility spectrum disorder. In comparison to the diagnostic criteria of hypermobile Ehlers–Danlos syndrome, the criteria for hypermobile spectrum disorder are less strict. However, these criteria are differentiated from criteria of other EDS types and therefore its less-strict criteria are only comparable to the criteria of hEDS. As those with HSD experience a considerable amount of discomfort, it is important to focus on the treatment, not the labels. The severity of each condition can be equivalent. In particular, musculoskeletal involvement is a requirement for diagnosis with any form of hypermobility spectrum disorder but not for hypermobile Ehlers–Danlos syndrome. Like hypermobile Ehlers–Danlos syndrome, hypermobility spectrum disorders are associated with orthostatic tachycardia, gastrointestinal disorders, and pelvic and bladder dysfunction.
Sources: en.wikipedia.org
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.
Mass spectrometry gives the observed molecular mass, which is compared with the calculated value for the expected sequence. Reversed-phase chromatography shows retention behaviour and main peak purity. Peptide mapping adds sequence-level confirmation when the question requires it.
Typical entries include appearance, chromatographic purity as area percent, observed mass, water or residual solvent content, and the analytical methods used. The document reflects the lot tested and the laboratory that performed the work. It does not by itself establish that the delivered vial matches the tested lot.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.